trending Market Intelligence /marketintelligence/en/news-insights/trending/zVOaBSdL5VrMQc5d21zzIQ2 content esgSubNav
In This List

Galena Biopharma stockholders approve merger with SELLAS Life Sciences

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Galena Biopharma stockholders approve merger with SELLAS Life Sciences

Galena Biopharma Inc. stockholders approved all proposals necessary for the company's merger agreement with Switzerland-based SELLAS Life Sciences Group Ltd.

The stockholders also approved a reverse stock split of Galena common shares at a ratio of not less than 1-for-10 and not greater than 1-for-30.

Galena's board has determined and SELLAS has agreed to effect the reverse stock split of the Galena common stock at a ratio of 1-for-30.

The reverse stock split is expected to become effective at 4:15 p.m. ET on Dec. 29. The merger is expected to close shortly after the effectiveness of the reverse stock split.

The combined company will be renamed SELLAS Life Sciences Group Inc. and will commence trading on the Nasdaq Capital Market on a post-reverse stock split basis under the new symbol SLS from Jan. 2, 2018.